Healthcare >> CEO Interviews >> March 22, 2019

Interview with the President and CEO: SCYNEXIS, Inc. (NASDAQ:SCYX)

Taglietti, Marco
Marco Taglietti, M.D., is President and Chief Executive Officer of SCYNEXIS, Inc. Dr. Taglietti joined SCYNEXIS as a member of the board in November 2014 and has been the Chief Executive Officer since April 2015 and the President since September 2015. Prior to SCYNEXIS, he served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and as President of the Forest Research Institute until its acquisition by Actavis in 2014. Prior to joining Forest Laboratories in 2007, Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development at Stiefel Laboratories, Inc., a GSK company, for three years. He joined Stiefel Laboratories after 12 years at Schering-Plough Corporation, where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. Dr. Taglietti currently serves on the board of directors of BioNJ, Inc. and Delcath (NASDAQ:DCTH). He received his medical degree and board certifications from the University of Pavia in Italy. Profile
Word count: 3,951

TWST: Could you give us a brief overview of SCYNEXIS at this time?

Dr. Taglietti: SCYNEXIS is a biotech company focused on developing new